Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis
Summary This post hoc analysis of a randomized, double-blind study of postmenopausal women with osteoporosis found that there were early increases in bone turnover markers and decreases in bone mineral density after discontinuation of long-term alendronate. These findings might help guide treatment...
Gespeichert in:
| Veröffentlicht in: | Osteoporosis international 2021-09, Vol.32 (9), p.1879-1888 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1888 |
|---|---|
| container_issue | 9 |
| container_start_page | 1879 |
| container_title | Osteoporosis international |
| container_volume | 32 |
| creator | Saag, K. Cosman, F. De Villiers, T. Langdahl, B. Scott, B.B. Denker, A.E. Pong, A. Santora, A.C. |
| description | Summary
This post hoc analysis of a randomized, double-blind study of postmenopausal women with osteoporosis found that there were early increases in bone turnover markers and decreases in bone mineral density after discontinuation of long-term alendronate. These findings might help guide treatment decisions, including monitoring after alendronate withdrawal.
Introduction
The short-term effects of discontinuing long-term bisphosphonates are poorly characterized. This post hoc analysis investigated 1–12-month changes in bone mineral density (BMD) and bone turnover markers (BTM) after alendronate (ALN) discontinuation.
Methods
Data were from a randomized, double-blind trial of MK-5442 (calcium-sensing receptor antagonist) following oral bisphosphonates, with placebo and continued ALN controls (
ClinicalTrials.gov
NCT00996801). Postmenopausal women with osteoporosis had received oral bisphosphonate (≥ 3–4 preceding years; ALN for the 12 months pre-screening), continuing on ALN 70 mg/week (
n
= 87) or placebo (
n
= 88).
Results
At 12 months, least-squares mean percent changes from baseline BMD (placebo vs. ALN) were lumbar spine (LS): – 0.36 vs. 1.29, total hip: – 1.44 vs. 0.46, and femoral neck (FN): – 1.26 vs. – 0.08 (all
P <
0.05). BTM levels increased by 1–3 months, to 12 months, with placebo vs. ALN (
P
< 0.001). FN BMD decline was greater in the placebo subgroup with higher urinary N-terminal cross-linked telopeptides of type I collagen/creatinine [uNTx/Cr] (
P
< 0.01), and higher serum N-terminal pro-peptide of type 1 collagen [P1NP] levels (
P
< 0.05), at baseline. There was a trend toward greater FN BMD loss with higher BTM levels at 3 and/or 6 months. Younger age and higher LS BMD at baseline were associated with greater LS BMD loss at 12 months (
P
= 0.04 and < 0.01, respectively); higher baseline FN BMD predicted greater FN BMD loss (
P
= 0.04).
Conclusion
Early changes in BTM levels and BMD were observed after discontinuation of long-term ALN. Further characterization of factors associated with patients’ risk of bone loss upon bisphosphonate discontinuation is warranted. |
| doi_str_mv | 10.1007/s00198-020-05785-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2564322449</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2564322449</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-fb9346f71ad2256a9a0154bbfe2f47965496b4fff52140d0cdfcba8463a827d83</originalsourceid><addsrcrecordid>eNp9kMtKAzEUhoMotlZfwIUEXEdzm0vcSakXENwouAuZmaRNmSY1SYXufXBTp-rORTiQ_3I4HwDnBF8RjKvriDERNcIUI1xUdYHYARgTzhiioiwOwRgLViHBydsInMS4xDkkRHUMRoyVuMS8GIPPmQr9FrYL5eY6Qutg452GaROc_9ABKtcNPyvrdFA97LSLNm2hMinLnY2td8m6jUrWO-gN7L2bo6ytoN_5GxvXC797TiUdb6CCax8TXPg2l6t-G208BUdG9VGf7ecEvN7NXqYP6On5_nF6-4RaVhUJmUYwXpqKqI7SolRCYVLwpjGaGl7lk7koG26MKSjhuMNtZ9pG1bxkqqZVV7MJuBx618G_b3RMcunzoXmlzH2cUcq5yC46uNrgYwzayHWwKxW2kmC5Ay8H8DKDl9_gJcuhi331plnp7jfyQzob2GCIWcqsw9_uf2q_ALzfkMY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2564322449</pqid></control><display><type>article</type><title>Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Saag, K. ; Cosman, F. ; De Villiers, T. ; Langdahl, B. ; Scott, B.B. ; Denker, A.E. ; Pong, A. ; Santora, A.C.</creator><creatorcontrib>Saag, K. ; Cosman, F. ; De Villiers, T. ; Langdahl, B. ; Scott, B.B. ; Denker, A.E. ; Pong, A. ; Santora, A.C.</creatorcontrib><description>Summary
This post hoc analysis of a randomized, double-blind study of postmenopausal women with osteoporosis found that there were early increases in bone turnover markers and decreases in bone mineral density after discontinuation of long-term alendronate. These findings might help guide treatment decisions, including monitoring after alendronate withdrawal.
Introduction
The short-term effects of discontinuing long-term bisphosphonates are poorly characterized. This post hoc analysis investigated 1–12-month changes in bone mineral density (BMD) and bone turnover markers (BTM) after alendronate (ALN) discontinuation.
Methods
Data were from a randomized, double-blind trial of MK-5442 (calcium-sensing receptor antagonist) following oral bisphosphonates, with placebo and continued ALN controls (
ClinicalTrials.gov
NCT00996801). Postmenopausal women with osteoporosis had received oral bisphosphonate (≥ 3–4 preceding years; ALN for the 12 months pre-screening), continuing on ALN 70 mg/week (
n
= 87) or placebo (
n
= 88).
Results
At 12 months, least-squares mean percent changes from baseline BMD (placebo vs. ALN) were lumbar spine (LS): – 0.36 vs. 1.29, total hip: – 1.44 vs. 0.46, and femoral neck (FN): – 1.26 vs. – 0.08 (all
P <
0.05). BTM levels increased by 1–3 months, to 12 months, with placebo vs. ALN (
P
< 0.001). FN BMD decline was greater in the placebo subgroup with higher urinary N-terminal cross-linked telopeptides of type I collagen/creatinine [uNTx/Cr] (
P
< 0.01), and higher serum N-terminal pro-peptide of type 1 collagen [P1NP] levels (
P
< 0.05), at baseline. There was a trend toward greater FN BMD loss with higher BTM levels at 3 and/or 6 months. Younger age and higher LS BMD at baseline were associated with greater LS BMD loss at 12 months (
P
= 0.04 and < 0.01, respectively); higher baseline FN BMD predicted greater FN BMD loss (
P
= 0.04).
Conclusion
Early changes in BTM levels and BMD were observed after discontinuation of long-term ALN. Further characterization of factors associated with patients’ risk of bone loss upon bisphosphonate discontinuation is warranted.</description><identifier>ISSN: 0937-941X</identifier><identifier>EISSN: 1433-2965</identifier><identifier>DOI: 10.1007/s00198-020-05785-3</identifier><identifier>PMID: 33606045</identifier><language>eng</language><publisher>London: Springer London</publisher><subject>Alendronic acid ; Bisphosphonates ; Bone Density ; Bone loss ; Bone mineral density ; Bone Remodeling ; Bone turnover ; Calcium antagonists ; Collagen (type I) ; Creatinine ; Diphosphonates - adverse effects ; Endocrinology ; Female ; Humans ; Lumbar Vertebrae ; Medicine ; Medicine & Public Health ; Original Article ; Orthopedics ; Osteoporosis ; Osteoporosis, Postmenopausal - drug therapy ; Placebos ; Post-menopause ; Rheumatology ; Spine (lumbar)</subject><ispartof>Osteoporosis international, 2021-09, Vol.32 (9), p.1879-1888</ispartof><rights>International Osteoporosis Foundation and National Osteoporosis Foundation 2021</rights><rights>2021. International Osteoporosis Foundation and National Osteoporosis Foundation.</rights><rights>International Osteoporosis Foundation and National Osteoporosis Foundation 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-fb9346f71ad2256a9a0154bbfe2f47965496b4fff52140d0cdfcba8463a827d83</citedby><cites>FETCH-LOGICAL-c375t-fb9346f71ad2256a9a0154bbfe2f47965496b4fff52140d0cdfcba8463a827d83</cites><orcidid>0000-0002-3377-5318 ; 0000-0001-6040-7935 ; 0000-0003-4554-6616 ; 0000-0001-6189-8078 ; 0000-0002-8712-7199</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00198-020-05785-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00198-020-05785-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33606045$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saag, K.</creatorcontrib><creatorcontrib>Cosman, F.</creatorcontrib><creatorcontrib>De Villiers, T.</creatorcontrib><creatorcontrib>Langdahl, B.</creatorcontrib><creatorcontrib>Scott, B.B.</creatorcontrib><creatorcontrib>Denker, A.E.</creatorcontrib><creatorcontrib>Pong, A.</creatorcontrib><creatorcontrib>Santora, A.C.</creatorcontrib><title>Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis</title><title>Osteoporosis international</title><addtitle>Osteoporos Int</addtitle><addtitle>Osteoporos Int</addtitle><description>Summary
This post hoc analysis of a randomized, double-blind study of postmenopausal women with osteoporosis found that there were early increases in bone turnover markers and decreases in bone mineral density after discontinuation of long-term alendronate. These findings might help guide treatment decisions, including monitoring after alendronate withdrawal.
Introduction
The short-term effects of discontinuing long-term bisphosphonates are poorly characterized. This post hoc analysis investigated 1–12-month changes in bone mineral density (BMD) and bone turnover markers (BTM) after alendronate (ALN) discontinuation.
Methods
Data were from a randomized, double-blind trial of MK-5442 (calcium-sensing receptor antagonist) following oral bisphosphonates, with placebo and continued ALN controls (
ClinicalTrials.gov
NCT00996801). Postmenopausal women with osteoporosis had received oral bisphosphonate (≥ 3–4 preceding years; ALN for the 12 months pre-screening), continuing on ALN 70 mg/week (
n
= 87) or placebo (
n
= 88).
Results
At 12 months, least-squares mean percent changes from baseline BMD (placebo vs. ALN) were lumbar spine (LS): – 0.36 vs. 1.29, total hip: – 1.44 vs. 0.46, and femoral neck (FN): – 1.26 vs. – 0.08 (all
P <
0.05). BTM levels increased by 1–3 months, to 12 months, with placebo vs. ALN (
P
< 0.001). FN BMD decline was greater in the placebo subgroup with higher urinary N-terminal cross-linked telopeptides of type I collagen/creatinine [uNTx/Cr] (
P
< 0.01), and higher serum N-terminal pro-peptide of type 1 collagen [P1NP] levels (
P
< 0.05), at baseline. There was a trend toward greater FN BMD loss with higher BTM levels at 3 and/or 6 months. Younger age and higher LS BMD at baseline were associated with greater LS BMD loss at 12 months (
P
= 0.04 and < 0.01, respectively); higher baseline FN BMD predicted greater FN BMD loss (
P
= 0.04).
Conclusion
Early changes in BTM levels and BMD were observed after discontinuation of long-term ALN. Further characterization of factors associated with patients’ risk of bone loss upon bisphosphonate discontinuation is warranted.</description><subject>Alendronic acid</subject><subject>Bisphosphonates</subject><subject>Bone Density</subject><subject>Bone loss</subject><subject>Bone mineral density</subject><subject>Bone Remodeling</subject><subject>Bone turnover</subject><subject>Calcium antagonists</subject><subject>Collagen (type I)</subject><subject>Creatinine</subject><subject>Diphosphonates - adverse effects</subject><subject>Endocrinology</subject><subject>Female</subject><subject>Humans</subject><subject>Lumbar Vertebrae</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Osteoporosis</subject><subject>Osteoporosis, Postmenopausal - drug therapy</subject><subject>Placebos</subject><subject>Post-menopause</subject><subject>Rheumatology</subject><subject>Spine (lumbar)</subject><issn>0937-941X</issn><issn>1433-2965</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kMtKAzEUhoMotlZfwIUEXEdzm0vcSakXENwouAuZmaRNmSY1SYXufXBTp-rORTiQ_3I4HwDnBF8RjKvriDERNcIUI1xUdYHYARgTzhiioiwOwRgLViHBydsInMS4xDkkRHUMRoyVuMS8GIPPmQr9FrYL5eY6Qutg452GaROc_9ABKtcNPyvrdFA97LSLNm2hMinLnY2td8m6jUrWO-gN7L2bo6ytoN_5GxvXC797TiUdb6CCax8TXPg2l6t-G208BUdG9VGf7ecEvN7NXqYP6On5_nF6-4RaVhUJmUYwXpqKqI7SolRCYVLwpjGaGl7lk7koG26MKSjhuMNtZ9pG1bxkqqZVV7MJuBx618G_b3RMcunzoXmlzH2cUcq5yC46uNrgYwzayHWwKxW2kmC5Ay8H8DKDl9_gJcuhi331plnp7jfyQzob2GCIWcqsw9_uf2q_ALzfkMY</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Saag, K.</creator><creator>Cosman, F.</creator><creator>De Villiers, T.</creator><creator>Langdahl, B.</creator><creator>Scott, B.B.</creator><creator>Denker, A.E.</creator><creator>Pong, A.</creator><creator>Santora, A.C.</creator><general>Springer London</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0002-3377-5318</orcidid><orcidid>https://orcid.org/0000-0001-6040-7935</orcidid><orcidid>https://orcid.org/0000-0003-4554-6616</orcidid><orcidid>https://orcid.org/0000-0001-6189-8078</orcidid><orcidid>https://orcid.org/0000-0002-8712-7199</orcidid></search><sort><creationdate>20210901</creationdate><title>Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis</title><author>Saag, K. ; Cosman, F. ; De Villiers, T. ; Langdahl, B. ; Scott, B.B. ; Denker, A.E. ; Pong, A. ; Santora, A.C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-fb9346f71ad2256a9a0154bbfe2f47965496b4fff52140d0cdfcba8463a827d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Alendronic acid</topic><topic>Bisphosphonates</topic><topic>Bone Density</topic><topic>Bone loss</topic><topic>Bone mineral density</topic><topic>Bone Remodeling</topic><topic>Bone turnover</topic><topic>Calcium antagonists</topic><topic>Collagen (type I)</topic><topic>Creatinine</topic><topic>Diphosphonates - adverse effects</topic><topic>Endocrinology</topic><topic>Female</topic><topic>Humans</topic><topic>Lumbar Vertebrae</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Osteoporosis</topic><topic>Osteoporosis, Postmenopausal - drug therapy</topic><topic>Placebos</topic><topic>Post-menopause</topic><topic>Rheumatology</topic><topic>Spine (lumbar)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saag, K.</creatorcontrib><creatorcontrib>Cosman, F.</creatorcontrib><creatorcontrib>De Villiers, T.</creatorcontrib><creatorcontrib>Langdahl, B.</creatorcontrib><creatorcontrib>Scott, B.B.</creatorcontrib><creatorcontrib>Denker, A.E.</creatorcontrib><creatorcontrib>Pong, A.</creatorcontrib><creatorcontrib>Santora, A.C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Osteoporosis international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saag, K.</au><au>Cosman, F.</au><au>De Villiers, T.</au><au>Langdahl, B.</au><au>Scott, B.B.</au><au>Denker, A.E.</au><au>Pong, A.</au><au>Santora, A.C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis</atitle><jtitle>Osteoporosis international</jtitle><stitle>Osteoporos Int</stitle><addtitle>Osteoporos Int</addtitle><date>2021-09-01</date><risdate>2021</risdate><volume>32</volume><issue>9</issue><spage>1879</spage><epage>1888</epage><pages>1879-1888</pages><issn>0937-941X</issn><eissn>1433-2965</eissn><abstract>Summary
This post hoc analysis of a randomized, double-blind study of postmenopausal women with osteoporosis found that there were early increases in bone turnover markers and decreases in bone mineral density after discontinuation of long-term alendronate. These findings might help guide treatment decisions, including monitoring after alendronate withdrawal.
Introduction
The short-term effects of discontinuing long-term bisphosphonates are poorly characterized. This post hoc analysis investigated 1–12-month changes in bone mineral density (BMD) and bone turnover markers (BTM) after alendronate (ALN) discontinuation.
Methods
Data were from a randomized, double-blind trial of MK-5442 (calcium-sensing receptor antagonist) following oral bisphosphonates, with placebo and continued ALN controls (
ClinicalTrials.gov
NCT00996801). Postmenopausal women with osteoporosis had received oral bisphosphonate (≥ 3–4 preceding years; ALN for the 12 months pre-screening), continuing on ALN 70 mg/week (
n
= 87) or placebo (
n
= 88).
Results
At 12 months, least-squares mean percent changes from baseline BMD (placebo vs. ALN) were lumbar spine (LS): – 0.36 vs. 1.29, total hip: – 1.44 vs. 0.46, and femoral neck (FN): – 1.26 vs. – 0.08 (all
P <
0.05). BTM levels increased by 1–3 months, to 12 months, with placebo vs. ALN (
P
< 0.001). FN BMD decline was greater in the placebo subgroup with higher urinary N-terminal cross-linked telopeptides of type I collagen/creatinine [uNTx/Cr] (
P
< 0.01), and higher serum N-terminal pro-peptide of type 1 collagen [P1NP] levels (
P
< 0.05), at baseline. There was a trend toward greater FN BMD loss with higher BTM levels at 3 and/or 6 months. Younger age and higher LS BMD at baseline were associated with greater LS BMD loss at 12 months (
P
= 0.04 and < 0.01, respectively); higher baseline FN BMD predicted greater FN BMD loss (
P
= 0.04).
Conclusion
Early changes in BTM levels and BMD were observed after discontinuation of long-term ALN. Further characterization of factors associated with patients’ risk of bone loss upon bisphosphonate discontinuation is warranted.</abstract><cop>London</cop><pub>Springer London</pub><pmid>33606045</pmid><doi>10.1007/s00198-020-05785-3</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-3377-5318</orcidid><orcidid>https://orcid.org/0000-0001-6040-7935</orcidid><orcidid>https://orcid.org/0000-0003-4554-6616</orcidid><orcidid>https://orcid.org/0000-0001-6189-8078</orcidid><orcidid>https://orcid.org/0000-0002-8712-7199</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0937-941X |
| ispartof | Osteoporosis international, 2021-09, Vol.32 (9), p.1879-1888 |
| issn | 0937-941X 1433-2965 |
| language | eng |
| recordid | cdi_proquest_journals_2564322449 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Alendronic acid Bisphosphonates Bone Density Bone loss Bone mineral density Bone Remodeling Bone turnover Calcium antagonists Collagen (type I) Creatinine Diphosphonates - adverse effects Endocrinology Female Humans Lumbar Vertebrae Medicine Medicine & Public Health Original Article Orthopedics Osteoporosis Osteoporosis, Postmenopausal - drug therapy Placebos Post-menopause Rheumatology Spine (lumbar) |
| title | Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T13%3A18%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20changes%20in%20bone%20turnover%20and%20bone%20mineral%20density%20after%20discontinuation%20of%20long-term%20oral%20bisphosphonates:%20a%20post%20hoc%20analysis&rft.jtitle=Osteoporosis%20international&rft.au=Saag,%20K.&rft.date=2021-09-01&rft.volume=32&rft.issue=9&rft.spage=1879&rft.epage=1888&rft.pages=1879-1888&rft.issn=0937-941X&rft.eissn=1433-2965&rft_id=info:doi/10.1007/s00198-020-05785-3&rft_dat=%3Cproquest_cross%3E2564322449%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2564322449&rft_id=info:pmid/33606045&rfr_iscdi=true |